|
|
|
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) |
|
|
|
| |
Ultragenyx Pharmaceutical Inc Outlook |
On February 13 2025 the Ultragenyx Pharmaceutical Inc provided following guidance
nnUltragenyx Pharmaceutical Inc. Overview and Financial Highlights for 2024nn
On February 13, 2025, Ultragenyx Pharmaceutical Inc. released its financial results for the fourth quarter and the entirety of fiscal year 2024, along with a comprehensive corporate update.
The company reported a robust total revenue of $560 million for 2024, surpassing their previously set guidance. This notable achievement underscores the strong market performance and demand for their key treatments. Among the highlights, Crysvita generated impressive revenue of $410 million, while Dojolvi contributed $88 million to the total.
2024 Total Revenue reached $560 million, exceeding previous guidance
Crysvita revenues accounted for $410 million; Dojolvi revenues were $88 million ,
|
On January 12 2025 the Ultragenyx Pharmaceutical Inc provided following guidance
nnUltragenyx Pharmaceutical Inc. Provides Financial Outlook for 2025 and Updates on Pipeline Initiativesnn
Ultragenyx Pharmaceutical Inc. has released preliminary estimates for its 2024 revenues, along with strategic financial guidance for the year 2025. The company anticipates its total revenue for 2024 to be approximately between $555 million and $560 million, surpassing the upper limit of prior forecasts. This optimistic outlook encompasses revenue streams generated from its flagship products: an estimated $405 million to $410 million from Crysvita and an anticipated $87 million to $89 million from Dojolvi.
Projected preliminary total revenue for 2024 ranging from $555 million to $560 million, exceeding previous guidance estimates; with Crysvita contributing between $405 million and $410 million, and Dojolvi contributing between $87 million and $89 million.
Looking ahead to 2025, Ultragenyx is poised to deliver not only significant revenue growth but also notable advancements in its developmental pipeline. The company’s strategic initiatives for the upcoming year are expected to reinforce its position in the rare disease market and enhance its product offerings.
Overall, this guidance reflects Ultragenyx's commitment to transparency and its proactive approach in navigating the complexities of the pharmaceutical landscape, ensuring that stakeholders remain informed about the company's financial health and future growth prospects.,
|
On January 7 2024 the Ultragenyx Pharmaceutical Inc provided following guidance
Ultragenyx Pharmaceutical Inc. has released a preliminary report on its estimated 2023 revenue, as well as provided guidance for its 2024 revenue and cash usage, along with updates on its pipeline and upcoming milestones for 2024.
According to the preliminary report, Ultragenyx expects its total revenue for 2023 to range between $430 million and $435 million. This figure includes the expected revenue from two of its key products, Crysvita and Dojolvi. Crysvita is projected to contribute revenue in the range of $325 million to $330 million, while Dojolvi is expected to generate revenue of approximately $70 million to $71 million in 2023.
Looking ahead to 2024, Ultragenyx has shared its guidance on revenue and cash usage for the year. Although specific figures were not provided in the report, the company anticipates a continued growth trajectory in revenue for the upcoming year. Additionally, Ultragenyx has outlined its plans for cash usage in 2024, which will likely be aligned with its strategic goals and priorities.
In terms of its pipeline, Ultragenyx provided updates on the progress of its ongoing research and development activities. The company is focused on advancing its portfolio of innovative therapies and expanding its product offerings. Ultragenyx has also highlighted key milestones it aims to achieve in 2024, indicating its commitment to delivering on its strategic objectives.
By providing this comprehensive update, Ultragenyx Pharmaceutical Inc. demonstrates transparency in reporting its financial performance and offers insights into its future prospects.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
